Sodium Polystyrene Sulfonate

×

Overview

What is Sodium Polystyrene Sulfonate?

Sodium Polystyrene Sulfonate Powder, for Suspension is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:

The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq ( approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or rectally as an enema.

One gram of Sodium Polystyrene Sulfonate Powder, for Suspension contains 4.1 mEq of sodium.

What does Sodium Polystyrene Sulfonate look like?

What are the available doses of Sodium Polystyrene Sulfonate?

Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder

What should I talk to my health care provider before I take Sodium Polystyrene Sulfonate?

How should I use Sodium Polystyrene Sulfonate?

Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia.

Limitation of Use:

Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action .

Administer Sodium Polystyrene Sulfonate Powder, for Suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation

What interacts with Sodium Polystyrene Sulfonate?

Sorry No Records found

What are the warnings of Sodium Polystyrene Sulfonate?

Sorry No Records found

What are the precautions of Sodium Polystyrene Sulfonate?

Sorry No Records found

What are the side effects of Sodium Polystyrene Sulfonate?

Sorry No records found

What should I look out for while using Sodium Polystyrene Sulfonate?

Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions:

● Hypersensitivity to polystyrene sulfonate resins

● Obstructive bowel disease

● Neonates with reduced gut motility

What might happen if I take too much Sodium Polystyrene Sulfonate?

Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.

How should I store and handle Sodium Polystyrene Sulfonate?

Epinephrine is light sensitive and should be stored in the outer case provided to protect it from light. Store at 20°to 25°C (68°to 77°F); excursions permitted to 15°to 30°C (59°to 86°F) [See USP Controlled Room Temperature]. Do not refrigerate. Before using, check to make sure the solution in the auto-injector is clear and colorless. Replace the auto-injector if the solution is discolored, cloudy, or contains particles.Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g). NDC 42806-013-96.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g). NDC 42806-013-96.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Sodium Polystyrene Sulfonate Powder, for Suspension is a non-absorbed, cation exchange polymer that contains a sodium counterion.

Sodium Polystyrene Sulfonate Powder, for Suspension increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.

As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable.

Non-Clinical Toxicology

Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions:

● Hypersensitivity to polystyrene sulfonate resins

● Obstructive bowel disease

● Neonates with reduced gut motility

Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with Sodium Polystyrene Sulfonate Powder, for Suspension use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.

● Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.

● Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction).

Discontinue use in patients who develop constipation.

The following adverse reactions are discussed elsewhere in the labeling:

● Intestinal Necrosis

● Electrolyte Disturbances

● Aspiration

The following adverse reactions have been identified during post-approval use of Sodium Polystyrene Sulfonate Powder, for Suspension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)

Metabolic:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: